1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 16 NOVEMBER 2015

Cancer Drug News 16 NOVEMBER 2015

  • November 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Early Companion Diagnostic Implementation To Rise
Industry Brief - Immunomedics' Sacituzumab Govitecan Improves PFS In Phase II TNBC Study
Industry Brief - AbbVie Submits Imbruvica Phase III Combination Data To FDA
Industry Trend Analysis - Tagrisso Will Take Market Share With Accelerated Approval
Industry Trend Analysis - Boston Scientific To Target Liver Cancer In Emerging Markets
Industry Brief - Transgene/SillaJen Revise Pexa-Vec Agreement
Industry Brief - Array/Pierre Fabre To Co-Develop Binimetinib And Encorafenib
Industry Trend Analysis - Cotellic/Zelboraf Potential Lies Beyond Melanoma
Industry Brief - BIND's Accurin Platform Shown To Improve Efficacy/Tolerability Of Multiple Anticancer Agents
Industry Brief - ArQule Presents Positive Data From Proprietary Oncology Pipeline
Industry Trend Analysis - PoC Testing Expands Reach
Industry Trend Analysis - Growing Cancer Burden To Provide Revenue Earning Opportunities
Industry Trend Analysis - Deep Pipeline Shifts Driving Industry-Wide Manufacturing Network Changes

Table Of Contents

Cancer Drug News 16 NOVEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Pathology Statistics in the US and the UK

  • December 2016
    12 pages
  • Pathology  

    Digestive Syste...  

    Cancer  

  • United States  

    United Kingdom  

View report >

Pathology Statistics in the US and the UK

  • December 2016
    13 pages
  • Pathology  

    Digestive Syste...  

  • United States  

    United Kingdom  

View report >

Cancer Statistics in Europe - Forecast

  • December 2016
  • Cancer  

  • Europe  

    World  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.